Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7265798 | 0.89 | POLB (0.48) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL580023 | 0.84 | POLB (0.52) | POLBKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3713227 | 0.84 | POLB (0.50) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL31204508 | 0.84 | POLB (0.50) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL3922931 | 0.83 | POLB (0.53) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL18033973 | 0.81 | HTT (0.44) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL9737304 | 0.81 | ALDH1A1 (0.52) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL347578 | 0.77 | LMNA (0.50) | POLBKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL22754120 | 0.76 | CYP3A4 (0.50) | POLBHTTTSHRKMT2AMEN1 | |
| SCHEMBL7011993 | 0.76 | POLB (0.46) | POLBHTTTSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7432283-B2 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005077363-A1 | HETEROCYCLIC GABA-A SUBTYPE SELECTIVE RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | LOUGHHEAD DAVID GARRETT (US) | 2005-01-20 | — | — | US | disclosed |
| US-6821984-B2 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES | SYNTEX (U.S.A.) LLC | 2004-11-23 | — | — | US | disclosed |
| EP-1453832-A1 | RING FUSED PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040006066-A1 | Ring fused pyrazole derivatives as CRF antagonists | SYNTEX (U.S.A.) LLC | 2004-01-08 | — | — | US | disclosed |
| WO-2003048160-A1 | RING FUSED PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | POLB 2744/4885HTT 854/4885TSHR 144/4885 |
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | POLB 4388/4885HTT 2014/4885TSHR 742/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | POLB 2744/4885HTT 854/4885TSHR 144/4885 |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | POLB 4673/4885HTT 2534/4885TSHR 244/4885 |
| US-20040006066-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | POLB 4603/4885HTT 2829/4885TSHR 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.